Morrisville, NC, USA – BioMedomics, a leader in innovative clinical diagnostics products that address global healthcare needs, proudly announced a partnership today with Ade Adebisi, professional rugby player and Sickle Cell Disease advocate, to officially represent the company’s Sickle SCAN product. Sickle SCAN is the world’s first rapid test to help diagnose Sickle Cell Disease (SCD) and Sickle Cell Trait (SCT).
“We are proud and honored to have Ade Adebisi represent our Sickle SCAN brand,” said BioMedomics CEO Frank Wang. “He is a passionate advocate for raising awareness for SCD and as a living example of someone who has successfully managed the disease, he is a tremendous inspiration to everyone in the SCD community.”
Ade Adebisi is a British/Nigerian rugby league footballer who also played rugby for the British Rugby League Association (BARLA), with the London Skolars, the London Broncos, Hull FC, Doncaster Lakers, Featherstone Rovers and Whitehaven. He is currently the Vice Chairman and General Manager of the Nigeria Rugby League Association (NRLA). As perhaps the only rugby player with SCD to ever play professionally, Adebisi continues to strive against all odds and encourage young men and women across the globe who struggle with the disease.
“Awareness starts with knowing if you either have the disease, or if you carry the genetic trait,” said Adebisi. “Sickle SCAN is the world’s first diagnostic rapid test that can help determine both, and is a great solution for places like Nigeria and other sub-Saharan African countries where access to traditional laboratory testing isn’t very easy. I’m excited for the impact that Sickle SCAN can have on helping to improve people’s lives.”
What is Sickle Cell Disease?
Sickle Cell Disease (SCD) is an inherited blood disorder which often causes red blood cells to become sickle-shaped through the presence of the abnormal hemoglobin S variant. Highly rigid sickle-shaped blood may have difficulty passing through small blood vessels, blocking normal blood flow, damaging tissues, and ultimately leading to many of the complications of SCD. Additionally, cells containing mostly hemoglobin S live only about 16 days compared to 120 days for normal red blood cells.
To initiate life-saving therapies, early diagnosis of SCD is key. Preventing the disease starts with individuals knowing whether they are carriers, since the disease can only be passed on when both parents have the gene for SCD.
About BioMedomics Sickle SCAN:
BioMedomics Sickle SCAN is a multiplexed, qualitative, point-of-care immunoassay used for the rapid diagnosis of sickle cell disorders. The test is made up of three proprietary indicators which detect the presence of hemoglobins A, S, and C, allowing the user to rapidly distinguish between normal, carrier, and sickle cell disease samples.
Before Sickle SCAN, SCD and SCT diagnosis was only possible using complex lab equipment. In low-resource regions where the disease is responsible for 9% of all under-five infant mortality, infrastructure challenges make central lab testing impractical. Sickle SCAN helps overcome the diagnostic gap. Ideal for providing quick and accurate results at the point-of-care, the test requires no supporting equipment and can also be used preventatively for genetic counseling to reduce the incidence of sickle cell births.
About BioMedomics, Inc.
BioMedomics is a leader in innovative clinical diagnostics products that address global healthcare needs. Quick, easy, and affordable, the company’s point-of-care products are designed to be used anytime, anywhere, bringing accurate clinical results to the most vulnerable members of society. By placing immediate healthcare knowledge in the hands of individuals and their healthcare providers, the company aims to empower rapid treatment decisions which save and improve lives.
Founded in 2007, BioMedomics is a privately-held company located in Morrisville, North Carolina.
###
MEDIA CONTACTS
For BioMedomics:
Mr. Kent Lupino
+1 984 464 3571
For Ade Adebisi:
Ms. Shalom Lloyd
shalom@naturallytribalgroup.com
+44 (0) 776 8878 207
Comments are closed for this article!